Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Opus Genetics ( (IRD) ) has issued an announcement.
On November 5, 2025, Opus Genetics, Inc. entered into a securities purchase agreement with affiliates of Perceptive Advisors LLC, Nantahala Capital Management, LLC, and Balyasny Asset Management L.P. for a registered direct offering. The company plans to issue and sell shares and pre-funded warrants, expecting to raise approximately $23 million to support its gene therapy clinical programs and general corporate purposes. The offering is set to close around November 7, 2025, and involves no placement agent or underwriter, minimizing costs for Opus Genetics.
The most recent analyst rating on (IRD) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.
Spark’s Take on IRD Stock
According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.
Opus Genetics faces significant financial challenges, with declining revenues and persistent losses undermining its financial stability. The technical indicators suggest a bearish trend, while the negative corporate event further highlights financing difficulties. These factors contribute to a low overall score, indicating a high-risk investment with uncertain prospects.
To see Spark’s full report on IRD stock, click here.
More about Opus Genetics
Opus Genetics, Inc. operates within the biotechnology industry, focusing on gene therapy clinical programs. The company is primarily engaged in advancing treatments for genetic eye disorders, specifically targeting LCA5 and BEST-1 conditions.
Average Trading Volume: 374,207
Technical Sentiment Signal: Hold
Current Market Cap: $130M
For detailed information about IRD stock, go to TipRanks’ Stock Analysis page.